Submitted by Anonymous (not verified) on 29 May 2026 - 14:46
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised